NOT FOR DISTRIBUTION
Header cover image

Market Cap

₹4.6b

Last Updated

2021/04/16 12:09 UTC

Data Sources

Company Financials

Executive Summary

Lincoln Pharmaceuticals Limited manufactures and sells pharmaceutical products in India and internationally. More Details


Snowflake Analysis

Flawless balance sheet and undervalued.

Share Price & News

How has Lincoln Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: LINCOLN is not significantly more volatile than the rest of Indian stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: LINCOLN's weekly volatility (5%) has been stable over the past year.


Market Performance


7 Day Return

-1.0%

LINCOLN

1.5%

IN Pharmaceuticals

-2.3%

IN Market


1 Year Return

69.3%

LINCOLN

46.7%

IN Pharmaceuticals

70.8%

IN Market

Return vs Industry: LINCOLN exceeded the Indian Pharmaceuticals industry which returned 42.2% over the past year.

Return vs Market: LINCOLN underperformed the Indian Market which returned 74.1% over the past year.


Shareholder returns

LINCOLNIndustryMarket
7 Day-1.0%1.5%-2.3%
30 Day2.5%10.1%-0.002%
90 Day0.9%1.9%5.4%
1 Year69.3%69.3%48.0%46.7%73.4%70.8%
3 Year1.8%-0.6%60.1%55.6%27.8%20.2%
5 Year53.2%47.9%28.1%23.3%86.9%71.2%

Long-Term Price Volatility Vs. Market

How volatile is Lincoln Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Lincoln Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: LINCOLN (₹237.75) is trading below our estimate of fair value (₹690.45)

Significantly Below Fair Value: LINCOLN is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: LINCOLN is good value based on its PE Ratio (7.9x) compared to the IN Pharmaceuticals industry average (19.3x).

PE vs Market: LINCOLN is good value based on its PE Ratio (7.9x) compared to the Indian market (18.2x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate LINCOLN's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: LINCOLN is good value based on its PB Ratio (1.3x) compared to the IN Pharmaceuticals industry average (2.3x).


Future Growth

How is Lincoln Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

20.8%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Lincoln Pharmaceuticals has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Lincoln Pharmaceuticals performed over the past 5 years?

19.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: LINCOLN has high quality earnings.

Growing Profit Margin: LINCOLN's current net profit margins (13.9%) are higher than last year (13.2%).


Past Earnings Growth Analysis

Earnings Trend: LINCOLN's earnings have grown by 19.5% per year over the past 5 years.

Accelerating Growth: LINCOLN's earnings growth over the past year (14.9%) is below its 5-year average (19.5% per year).

Earnings vs Industry: LINCOLN earnings growth over the past year (14.9%) underperformed the Pharmaceuticals industry 39.9%.


Return on Equity

High ROE: LINCOLN's Return on Equity (16.8%) is considered low.


Financial Health

How is Lincoln Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: LINCOLN's short term assets (₹3.1B) exceed its short term liabilities (₹883.7M).

Long Term Liabilities: LINCOLN's short term assets (₹3.1B) exceed its long term liabilities (₹101.3M).


Debt to Equity History and Analysis

Debt Level: LINCOLN's debt to equity ratio (5.2%) is considered satisfactory.

Reducing Debt: LINCOLN's debt to equity ratio has reduced from 47.6% to 5.2% over the past 5 years.

Debt Coverage: LINCOLN's debt is well covered by operating cash flow (490.3%).

Interest Coverage: LINCOLN earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet


Dividend

What is Lincoln Pharmaceuticals's current dividend yield, its reliability and sustainability?

0.65%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: LINCOLN's dividend (0.65%) is higher than the bottom 25% of dividend payers in the Indian market (0.43%).

High Dividend: LINCOLN's dividend (0.65%) is low compared to the top 25% of dividend payers in the Indian market (1.9%).


Stability and Growth of Payments

Stable Dividend: LINCOLN's dividend payments have been volatile in the past 10 years.

Growing Dividend: LINCOLN's dividend payments have increased over the past 10 years.


Current Payout to Shareholders

Dividend Coverage: With its low payout ratio (5.1%), LINCOLN's dividend payments are thoroughly covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.8yrs

Average management tenure


CEO

Mahendrabhai Patel (66 yo)

2.83yrs

Tenure

₹2,308,000

Compensation

Mr. Mahendrabhai Gulabdas Patel, B.A, LLB serves as Managing Director of Lincoln Pharmaceuticals Ltd. Mr. Patel has varied experience of chemicals, steel, finance etc. Mr. Patel handles corporate planning ...


CEO Compensation Analysis

Compensation vs Market: Mahendrabhai's total compensation ($USD30.85K) is about average for companies of similar size in the Indian market ($USD41.03K).

Compensation vs Earnings: Mahendrabhai's compensation has increased by more than 20% in the past year.


Leadership Team

Experienced Management: LINCOLN's management team is considered experienced (2.8 years average tenure).


Board Members

Experienced Board: LINCOLN's board of directors are seasoned and experienced ( 23.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: LINCOLN insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Lincoln Pharmaceuticals Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Lincoln Pharmaceuticals Limited
  • Ticker: LINCOLN
  • Exchange: NSEI
  • Founded: 1979
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: ₹4.636b
  • Shares outstanding: 20.00m
  • Website: https://www.lincolnpharma.com

Number of Employees


Location

  • Lincoln Pharmaceuticals Limited
  • Lincoln House
  • Behind Satyam Complex
  • Ahmedabad
  • Gujarat
  • 380062
  • India

Listings


Biography

Lincoln Pharmaceuticals Limited manufactures and sells pharmaceutical products in India and internationally. It offers products in the areas of anti-infective, respiratory system, gynecology, cardio and CN...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/04/16 12:09
End of Day Share Price2021/04/16 00:00
Earnings2020/12/31
Annual Earnings2020/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.